The preliminary trial of chemoembolization with irinotecan-eluting beads on colorectal cancer metastases to the liver by Aliberti et al. demonstrated a 50–90% decrease in CEA levels and a decrease in lesional contrast enhancement [6]. This evidence concerns the gene CEACAM5 and colorectal cancer.